published meta-analysis   sensitivity analysis   studies

anticoagulant, curative dose in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20] COALIZAO ACTION, 2021 1.55 [0.90; 2.70] COVID-PACT, 2022 0.91 [0.56; 1.48] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38] 1.03[0.85; 1.25]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021416%4,320moderatenot evaluable clinical deteriorationdetailed resultsCOALIZAO ACTION, 2021 1.35 [0.85; 2.15] 1.35[0.85; 2.15]COALIZAO ACTION, 202110%615NAnot evaluable clinical improvementdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03] 0.83[0.67; 1.03]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,074NAnot evaluable clinical improvement (28-day)detailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57] 1.27[1.03; 1.57]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,219NAnot evaluable death or ventilationdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07] 0.82[0.63; 1.07]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,231NAnot evaluable Major thrombotic events or deathdetailed resultsCOVID-PACT, 2022 0.56 [0.32; 0.98] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36] 0.80[0.44; 1.46]COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021273%1,473moderatenot evaluable Major bleedingdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67] COALIZAO ACTION, 2021 2.50 [0.78; 8.06] COVID-PACT, 2022 3.86 [0.44; 34.07] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98] 1.80[1.15; 2.82]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, COALIZAO ACTION, 2021, COVID-PACT, 2022, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202140%4,314moderatenot evaluable Thromboembolic eventsdetailed resultsCOALIZAO ACTION, 2021 0.73 [0.41; 1.29] 0.73[0.41; 1.29]COALIZAO ACTION, 202110%614NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:01 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 830 - roots T: 290